Literature DB >> 17350876

Src kinase signaling in leukaemia.

Shaoguang Li1.   

Abstract

Role of Src kinases in acute lymphoblastic leukaemia has been recently demonstrated in leukaemia mouse model. Retained activation of Src kinases by the BCR-ABL oncoprotein in leukaemic cells following inhibition of BCR-ABL kinase activity by imatinib indicates that Src activation by BCR-ABL is independent of BCR-ABL kinase activity and provides an explanation for reduced effectiveness of the BCR-ABL kinase activity inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Simultaneous inhibition of kinase activity of both BCR-ABL and Src kinases results in long-term survival of mice with acute lymphoblastic leukaemia. Leukaemic stem cells exist in acute lymphoblastic leukaemia, and complete eradication of this group of cells would provide a curative therapy for this disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17350876      PMCID: PMC2063586          DOI: 10.1016/j.biocel.2007.01.027

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  54 in total

1.  The LCK gene is involved in the t(1;7)(p34;q34) in the T-cell acute lymphoblastic leukemia derived cell line, HSB-2.

Authors:  R C Burnett; J C David; A M Harden; M M Le Beau; J D Rowley; M O Diaz
Journal:  Genes Chromosomes Cancer       Date:  1991-11       Impact factor: 5.006

2.  p53 in chronic myelogenous leukemia in acute phase.

Authors:  E Feinstein; G Cimino; R P Gale; G Alimena; R Berthier; K Kishi; J Goldman; A Zaccaria; A Berrebi; E Canaani
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

3.  Elevated level of p60c-src in virus-transformed murine megakaryocytic cell lines.

Authors:  S Fischer; F Wendling; I Boulet; L Cocault; M Soula; R Fagard; P Tambourin
Journal:  Oncogene       Date:  1989-07       Impact factor: 9.867

4.  Interleukin-3 regulates the activity of the LYN protein-tyrosine kinase in myeloid-committed leukemic cell lines.

Authors:  T Torigoe; R O'Connor; D Santoli; J C Reed
Journal:  Blood       Date:  1992-08-01       Impact factor: 22.113

5.  Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase.

Authors:  T Skorski; M Nieborowska-Skorska; P Wlodarski; D Perrotti; R Martinez; M A Wasik; B Calabretta
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

6.  Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

Authors:  Thomas O'Hare; Roy Pollock; Eric P Stoffregen; Jeffrey A Keats; Omar M Abdullah; Erika M Moseson; Victor M Rivera; Hao Tang; Chester A Metcalf; Regine S Bohacek; Yihan Wang; Raji Sundaramoorthi; William C Shakespeare; David Dalgarno; Tim Clackson; Tomi K Sawyer; Michael W Deininger; Brian J Druker
Journal:  Blood       Date:  2004-07-15       Impact factor: 22.113

7.  Overriding imatinib resistance with a novel ABL kinase inhibitor.

Authors:  Neil P Shah; Chris Tran; Francis Y Lee; Ping Chen; Derek Norris; Charles L Sawyers
Journal:  Science       Date:  2004-07-16       Impact factor: 47.728

8.  Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenous leukemia.

Authors:  M Towatari; K Adachi; H Kato; H Saito
Journal:  Blood       Date:  1991-11-01       Impact factor: 22.113

9.  Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.

Authors:  Yiguo Hu; Yuhua Liu; Shawn Pelletier; Elisabeth Buchdunger; Markus Warmuth; Doriano Fabbro; Michael Hallek; Richard A Van Etten; Shaoguang Li
Journal:  Nat Genet       Date:  2004-04-18       Impact factor: 38.330

10.  Expression of the c-fgr and hck protein-tyrosine kinases in acute myeloid leukemic blasts is associated with early commitment and differentiation events in the monocytic and granulocytic lineages.

Authors:  C L Willman; C C Stewart; T L Longacre; D R Head; R Habbersett; S F Ziegler; R M Perlmutter
Journal:  Blood       Date:  1991-02-15       Impact factor: 22.113

View more
  9 in total

1.  Heme controls the regulation of protein tyrosine kinases Jak2 and Src.

Authors:  Xiao Yao; Parimaladevi Balamurugan; Aaron Arvey; Christina Leslie; Li Zhang
Journal:  Biochem Biophys Res Commun       Date:  2010-10-29       Impact factor: 3.575

Review 2.  Human T-lymphotropic virus proteins and post-translational modification pathways.

Authors:  Carlo Bidoia
Journal:  World J Virol       Date:  2012-08-12

3.  Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.

Authors:  Noriko Doki; Jiro Kitaura; Tomoyuki Uchida; Daichi Inoue; Yuki Kagiyama; Katsuhiro Togami; Masamichi Isobe; Shinichi Ito; Akie Maehara; Kumi Izawa; Naoko Kato; Toshihiko Oki; Yuka Harada; Fumio Nakahara; Hironori Harada; Toshio Kitamura
Journal:  Int J Hematol       Date:  2011-12-22       Impact factor: 2.490

4.  From Hen House to Bedside: Tracing Hanafusa's Legacy from Avian Leukemia Viruses to SRC to ABL and Beyond.

Authors:  Michael G Kharas; George Q Daley
Journal:  Genes Cancer       Date:  2010-12

5.  Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.

Authors:  Heiko Konig; Mhairi Copland; Su Chu; Richard Jove; Tessa L Holyoake; Ravi Bhatia
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

Review 6.  Imatinib: in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia.

Authors:  Sarah A Cross; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 7.  Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials.

Authors:  Margaret E Macy; Kelly K Sawczyn; Timothy P Garrington; Douglas K Graham; Lia Gore
Journal:  Curr Oncol Rep       Date:  2008-11       Impact factor: 5.075

8.  Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease.

Authors:  Anupriya Agarwal; Thomas G P Bumm; Amie S Corbin; Thomas O'Hare; Marc Loriaux; Jonathan VanDyke; Stephanie G Willis; Jutta Deininger; Keiichi I Nakayama; Brian J Druker; Michael W Deininger
Journal:  Blood       Date:  2008-06-17       Impact factor: 22.113

9.  Natural-Based Indirubins Display Potent Cytotoxicity toward Wild-Type and T315I-Resistant Leukemia Cell Lines.

Authors:  Nicolas Gaboriaud-Kolar; Vasillios Myrianthopoulos; Konstantina Vougogiannopoulou; Panagiotis Gerolymatos; David A Horne; Richard Jove; Emmanuel Mikros; Sangkil Nam; Alexios-Leandros Skaltsounis
Journal:  J Nat Prod       Date:  2016-10-11       Impact factor: 4.803

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.